Guggenheim began coverage on shares of Sionna Therapeutics (NASDAQ:SION - Free Report) in a report issued on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $45.00 price objective on the stock.
Sionna Therapeutics Stock Up 4.0 %
Shares of NASDAQ:SION traded up $0.62 during trading on Tuesday, reaching $16.27. 327,316 shares of the stock were exchanged, compared to its average volume of 225,817. Sionna Therapeutics has a 1-year low of $13.20 and a 1-year high of $25.19.
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
